Company news
Alkermes Plc (NASDAQ:ALKS) news
Every Alkermes Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
August 24, 2026
Alkermes plc Reports Second Quarter 2026 Financial Results
July 28, 2026
Alkermes to Report Second Quarter Financial Results on July 28, 2026
July 14, 2026
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extensio...
July 13, 2026
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
June 17, 2026
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
June 15, 2026
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
June 4, 2026
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Ann...
May 26, 2026
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Confere...
May 21, 2026
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults ...
May 12, 2026
Alkermes plc Reports First Quarter 2026 Financial Results
May 5, 2026
Alkermes to Report First Quarter Financial Results on May 5, 2026
April 21, 2026
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Acade...
April 16, 2026
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published ...
April 14, 2026
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
April 1, 2026
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
March 12, 2026
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
March 10, 2026
Alkermes plc Announces CEO Succession Plan
February 25, 2026
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
February 25, 2026
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
February 12, 2026
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
February 11, 2026
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
January 12, 2026
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
January 6, 2026
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
Alkermes to Participate in Two Upcoming Investor Conferences
November 25, 2025
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
November 19, 2025
Alkermes Response to Avadel Announcement
November 14, 2025
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
November 12, 2025
FORM 8.1(a) & (b) (Opening Position Disclosure)
November 5, 2025
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 4, 2025
Alkermes plc Reports Third Quarter 2025 Financial Results
October 28, 2025
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
October 22, 2025
Alkermes to Report Third Quarter Financial Results on October 28, 2025
October 20, 2025
Alkermes Appoints Joshua Reed as Chief Financial Officer
September 12, 2025
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
September 11, 2025
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Slee...
September 8, 2025
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at ...
August 25, 2025
National Veterinary Associates Welcomes Brian McKeon to Board of Directors
August 18, 2025
Alkermes plc Reports Second Quarter 2025 Financial Results
July 29, 2025
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
July 21, 2025
Alkermes to Report Second Quarter Financial Results on July 29, 2025
July 15, 2025
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
June 2, 2025
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
June 2, 2025
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
May 29, 2025
Alkermes plc Reports First Quarter 2025 Financial Results
May 1, 2025
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
April 30, 2025
Alkermes to Report First Quarter Financial Results on May 1, 2025
April 17, 2025
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 2, 2025